Mavorixafor
{{Short description|Chemical compound}}
{{Use American English|date=April 2024}}
{{Use dmy dates|date=April 2024}}
{{cs1 config |display-authors=6}}
{{Infobox drug
| image = Mavorixafor.svg
| width =
| alt =
| caption =
| pronounce =
| tradename = Xolremdi
| Drugs.com = {{drugs.com|mtm|mavorixafor}}
| MedlinePlus =
| DailyMedID = Mavorixafor
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = By mouth
| class = CXCR4 antagonist
| ATC_prefix = L03
| ATC_suffix = AX24
| ATC_supplemental =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 558447-26-0
| CAS_supplemental =
| PubChem = 11256587
| IUPHAR_ligand = 8580
| DrugBank = DB05501
| ChemSpiderID = 9431613
| UNII = 0G9LGB5O2W
| KEGG = D11510
| ChEBI = 138865
| ChEMBL = 518924
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = X4P-001; AMD-070
| IUPAC_name = {{prime|N}}-(1H-Benzimidazol-2-ylmethyl)-{{prime|N}}-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
| C=21|H=27|N=5
| SMILES = C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3
| StdInChI = 1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1
| StdInChI_comment =
| StdInChIKey = WVLHHLRVNDMIAR-IBGZPJMESA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome. It is a CXC chemokine receptor 4 antagonist. It is taken by mouth. It was developed by X4 Pharmaceuticals.
The most frequently reported adverse reactions include thrombocytopenia (low platelet counts), rash, rhinitis (stuffy nose), epistaxis (nosebleed), vomiting, and dizziness.
Mavorixafor was approved for medical use in the United States in April 2024.{{cite web | title=FDA approves first drug for WHIM syndrome, a rare disorder | website=U.S. Food and Drug Administration (FDA) | date=29 April 2024 | url=https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections | access-date=29 April 2024 | archive-date=29 April 2024 | archive-url=https://web.archive.org/web/20240429222855/https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections | url-status=live }} {{PD-notice}}{{cite web | title=Novel Drug Approvals for 2024 | website=U.S. Food and Drug Administration (FDA) | date=29 April 2024 | url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 | access-date=30 April 2024 | archive-date=30 April 2024 | archive-url=https://web.archive.org/web/20240430031024/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 | url-status=live }}{{cite press release | title=X4 Pharmaceuticals Announces FDA Approval of Xolremdi (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome | publisher=X4 Pharmaceuticals | via=GlobeNewswire | date=29 April 2024 | url=https://www.globenewswire.com/news-release/2024/04/29/2871050/0/en/X4-Pharmaceuticals-Announces-FDA-Approval-of-XOLREMDI-mavorixafor-Capsules-First-Drug-Indicated-in-Patients-with-WHIM-Syndrome.html | access-date=29 April 2024 | archive-date=29 April 2024 | archive-url=https://web.archive.org/web/20240429103703/https://www.globenewswire.com/news-release/2024/04/29/2871050/0/en/X4-Pharmaceuticals-Announces-FDA-Approval-of-XOLREMDI-mavorixafor-Capsules-First-Drug-Indicated-in-Patients-with-WHIM-Syndrome.html | url-status=live }} The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.{{cite report | title=New Drug Therapy Approvals 2024 | website=U.S. Food and Drug Administration (FDA) | date=January 2025 | url=https://www.fda.gov/media/184967/download | format=PDF | access-date=21 January 2025 | archive-url=https://web.archive.org/web/20250121045744/https://www.fda.gov/media/184967/download | archive-date=21 January 2025 | url-status=live }}
Medical uses
Adverse effects
Mavorixafor is expected to cause harm to the baby.
History
The effectiveness of mavorixafor was evaluated in a 52-week, randomized, double-blind, placebo-controlled trial that enrolled 31 adolescents and adults with WHIM syndrome (NCT03995108). Mavorixafor improved absolute neutrophil counts and absolute lymphocyte counts, assessed over a 24-hour period four times throughout the study. Absolute neutrophil counts below 500 cells/μL and absolute lymphocyte counts below 1000 cells/μL are associated with an increased risk of infections. The average length of time over 24 hours that counts were above these levels was significantly longer with mavorixafor compared to the placebo group (15.0 hours compared to 2.8 hours for absolute neutrophil counts; 15.8 hours compared to 4.6 hours for absolute lymphocyte counts).
Society and culture
= Names =
Mavorixafor is the international nonproprietary name.{{cite journal | vauthors = ((World Health Organization)) | year = 2018 | title = International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80 | journal = WHO Drug Information | volume = 32 | issue = 3 | hdl = 10665/330907 | hdl-access = free | author-link = World Health Organization }}
Research
Mavorixafor is in clinical trials for melanoma{{cite journal |last1=Andtbacka |first1=Robert H.I. |last2=Wang |first2=Yan |last3=Pierce |first3=Robert H. |last4=Campbell |first4=Jean S. |last5=Yushak |first5=Melinda |last6=Milhem |first6=Mohammed |last7=Ross |first7=Merrick |last8=Niland |first8=Katie |last9=Arbeit |first9=Robert D. |last10=Parasuraman |first10=Sudha |last11=Bickley |first11=Kris |last12=Yeung |first12=Cecilia CS |last13=Aicher |first13=Lauri D. |last14=Smythe |first14=Kimberly S. |last15=Gan |first15=Lu |title=Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma |journal=Cancer Research Communications |date=31 August 2022 |volume=2 |issue=8 |pages=904–913 |doi=10.1158/2767-9764.CRC-22-0090|doi-access=free |pmid=36923305 |pmc=10010370 }} and renal cell carcinoma.{{cite journal |last1=Choueiri |first1=Toni K. |last2=Atkins |first2=Michael B. |last3=Rose |first3=Tracy L. |last4=Alter |first4=Robert S. |last5=Ju |first5=Yawen |last6=Niland |first6=Katie |last7=Wang |first7=Yan |last8=Arbeit |first8=Robert |last9=Parasuraman |first9=Sudha |last10=Gan |first10=Lu |last11=McDermott |first11=David F. |title=A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy |journal=Investigational New Drugs |date=August 2021 |volume=39 |issue=4 |pages=1019–1027 |doi=10.1007/s10637-020-01058-2|pmid=33507454 |s2cid=231746027 }}
References
{{reflist}}
External links
- {{ClinicalTrialsGov|NCT03995108|Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome}}
{{Immunostimulants}}
{{Portal bar | Medicine}}
{{Authority control}}